Insmed Inc (INSM)vsVir Biotechnology Inc (VIR)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
VIR
Vir Biotechnology Inc
$8.99
+4.90%
HEALTHCARE · Cap: $1.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 785% more annual revenue ($606.42M vs $68.56M). VIR leads profitability with a 0.0% profit margin vs -2.1%. VIR earns a higher WallStSmart Score of 46/100 (D+).
INSM
Hold39
out of 100
Grade: F
VIR
Hold46
out of 100
Grade: D+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Earnings expanding 58.5% YoY
Reasonable price relative to book value
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
4.2% revenue growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -45.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : VIR
The strongest argument for VIR centers on EPS Growth, Price/Book.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : VIR
The primary concerns for VIR are Revenue Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while VIR is a value play — different risk/reward profiles.
VIR carries more volatility with a beta of 1.71 — expect wider price swings.
VIR is growing revenue faster at 4.2% — sustainability is the question.
VIR generates stronger free cash flow (-30M), providing more financial flexibility.
Bottom Line
VIR scores higher overall (46/100 vs 39/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Vir Biotechnology Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?